Zelboraf is indicated as a treatment for patients with unresectable or metastatic melanoma with BRAFV600E mutation.
Biologics will administer the Patient Partners program, a clinical support service through a primary care model that dedicates an oncology nurse to provide both disease and drug education and support services.
Biologics will also provide adverse event monitoring and reporting, therapy adherence assessments and side effect education and management.
Further, Genentech has selected Biologics’ oncology pharmacy as a strategic channel partner to dispense Zelboraf in the US.